[1] |
Fraint E, Holuba MJ, Wray L. Pediatric hematopoietic stem cell transplant[J]. Pediatr Rev, 2020, 41(11): 609-611.
doi: 10.1542/pir.2020-0130
pmid: 33139417
|
[2] |
Kelta M, Zekri J, Abdelghany E, et al. High-dose chemotherapy and peripheral hematopoietic stem cell transplantation in relapsed/refractory Hodgkin's lymphoma[J]. Tumori, 2018, 104(6): 471-475.
doi: 10.5301/tj.5000591
pmid: 28009428
|
[3] |
吴敏媛, 李志刚, 崔蕾. 儿童急性淋巴细胞白血病诊疗建议(第四次修订)[J]. 中华儿科杂志, 2014, 52(9): 641-644.
|
[4] |
顾龙君. 儿童急性髓细胞白血病诊疗建议[J]. 中华儿科杂志, 2006, 44(11): 877-878.
|
[5] |
陈静, 竺晓凡. 儿童获得性再生障碍性贫血诊疗建议[J]. 中华儿科杂志, 2014, 52(2): 103-106.
|
[6] |
高怡瑾, 汤静燕, 唐锁勤. 儿童霍奇金淋巴瘤的诊疗建议[J]. 中华儿科杂志, 2014, 52(8): 586-589.
|
[7] |
中国抗癌协会小儿肿瘤专业委员会, 中华医学会小儿外科学分会肿瘤外科学组. 儿童神经母细胞瘤诊疗专家共识[J]. 中华小儿外科杂志, 2015, 36(1): 3-7.
|
[8] |
简珊, 宋红梅. 儿童系统性硬化的治疗[J]. 中国小儿急救医学, 2013, 20(3): 244-247.
|
[9] |
何玺玉. X-连锁肾上腺脑白质营养不良的诊断与治疗[J]. 中华实用儿科临床杂志, 2015, 30(8): 561-564.
|
[10] |
陈静. 儿童恶性血液病异基因造血干细胞移植指征[J]. 中华妇幼临床医学杂志(电子版), 2014, 10(3): 13-17.
|
[11] |
Xu L, Chen H, Chen J, et al. The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology[J]. J Hematol Oncol, 2018, 11(1): 33.
doi: 10.1186/s13045-018-0564-x
|
[12] |
中华医学会血液学分会干细胞应用学组. 中国异基因造血干细胞移植治疗血液系统疾病专家共识(Ⅰ)——适应证、预处理方案及供者选择(2014年版)[J]. 中华血液学杂志, 2014, 35(8): 775-780.
|
[13] |
中华医学会血液学分会干细胞应用学组. 中国异基因造血干细胞移植治疗血液系统疾病专家共识(Ⅲ)——急性移植物抗宿主病(2020年版)[J]. 中华血液学杂志, 2020, 41(7): 529-536.
|
[14] |
Iftikhar R, Chaudhry QUN, Anwer F, et al. Allogeneic hematopoietic stem cell transplantation in aplastic anemia: current indications and transplant strategies[J]. Blood Rev, 2021, 47: 100772.
doi: 10.1016/j.blre.2020.100772
|
[15] |
Okamoto Y, Nakazawa Y, Inoue M, et al. Hematopoietic stem cell transplantation in children and adolescents with nonremission acute lymphoblastic leukemia[J]. Pediatr Blood Cancer, 2020, 67(12): e28732.
|
[16] |
Kongtim P, Ciurea SO. Who is the best donor for haploidentical stem cell transplantation?[J]. Semin Hematol, 2019, 56(3): 194-200.
doi: S0037-1963(18)30109-4
pmid: 31202430
|
[17] |
Metheny L, de Lima M. Hematopoietic stem cell transplant with HLA-mismatched grafts: impact of donor, source, conditioning, and graft versus host disease prophylaxis[J]. Expert Rev Hematol, 2019, 12(1): 47-60.
doi: 10.1080/17474086.2019.1562331
pmid: 30582393
|
[18] |
Rodríguez-Arbolí E, Martínez-Cuadrón D, Rodríguez-Veiga R, et al. Long-term outcomes after autologous versus allogeneic stem cell transplantation in molecularly-stratified patients with intermediate cytogenetic risk acute myeloid leukemia: a PETHEMA study[J]. Transplant Cell Ther, 2021, 27(4): 311.
|
[19] |
Toffalori C, Zito L, Gambacorta V, et al. Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation[J]. Nat Med, 2019, 25(4): 603-611.
doi: 10.1038/s41591-019-0400-z
pmid: 30911134
|
[20] |
Li H, Li X, Chen Y, et al. Sequential transplantation of haploidentical stem cell and unrelated cord blood with using ATG/PTCY increases survival of relapsed/refractory hematologic malignancies[J]. Front Immunol, 2021, 12: 733326.
doi: 10.3389/fimmu.2021.733326
|
[21] |
Zhu X, Tang B, Sun Z. Umbilical cord blood trans-plantation: still growing and improving[J]. Stem Cells Transl Med, 2021, 10(Suppl 2): S62-S74.
doi: 10.1002/sctm.20-0495
|
[22] |
Webster JA, Luznik L, Gojo I. Treatment of AML relapse after allo-HCT[J]. Front Oncol, 2021, 11: 812207.
doi: 10.3389/fonc.2021.812207
|
[23] |
Battipaglia G, Ruggeri A, Labopin M, et al. Refined graft-versus-host disease/relapse-free survival in transplant from HLA-identical related or unrelated donors in acute myeloid leukemia[J]. Bone Marrow Transplant, 2018, 53(10): 1295-1303.
doi: 10.1038/s41409-018-0169-6
|